Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

ClinicalTrials.gov ID: NCT02589847

Public ClinicalTrials.gov record NCT02589847. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Study identification

NCT ID: NCT02589847
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Rebiotix Inc.; Industry
Enrollment: 272 participants

Conditions and interventions

Conditions

Clostridium Difficile Infection

Interventions

RBX2660 Biological
Standard of Care Antibiotics Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2015
Primary completion: May 31, 2017
Completion: Feb 28, 2019
Last update posted: Mar 25, 2021

2015 – 2019

United States locations

U.S. sites: 28
U.S. states: 18
U.S. cities: 28

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85054	—
Not listed	North Little Rock	Arkansas	72117	—
Not listed	Sacramento	California	95817	—
Not listed	Bay Pines	Florida	33744	—
Not listed	Coral Springs	Florida	33065	—
Not listed	Gainesville	Florida	32610	—
Not listed	Miami	Florida	33101	—
Not listed	Idaho Falls	Idaho	83404	—
Not listed	Chicago	Illinois	60637	—
Not listed	Maywood	Illinois	60153	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Lafayette	Indiana	47904	—
Not listed	Lexington	Kentucky	40506	—
Not listed	Detroit	Michigan	48202	—
Not listed	Rochester	Minnesota	55905	—
Not listed	Saint Paul	Minnesota	55130	—
Not listed	St Louis	Missouri	63110	—
Not listed	Omaha	Nebraska	68198	—
Not listed	Flushing	New York	11355	—
Not listed	Rochester	New York	14618	—
Not listed	Syracuse	New York	52325	—
Not listed	The Bronx	New York	10468	—
Not listed	Fargo	North Dakota	58122	—
Not listed	Lima	Ohio	45801	—
Not listed	Jackson	Tennessee	38305	—
Not listed	Houston	Texas	77025	—
Not listed	Springfield	Virginia	22150	—
Not listed	Virginia Beach	Virginia	23454	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02589847, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 25, 2021 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02589847 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →